Walleye Trading LLC Takes $71,000 Position in Verastem, Inc. (NASDAQ:VSTM)

Walleye Trading LLC bought a new stake in Verastem, Inc. (NASDAQ:VSTMGet Rating) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 60,814 shares of the biopharmaceutical company’s stock, valued at approximately $71,000.

Other institutional investors also recently modified their holdings of the company. Wetherby Asset Management Inc. bought a new position in shares of Verastem in the first quarter valued at approximately $134,000. Hsbc Holdings PLC bought a new position in Verastem during the first quarter valued at $66,000. XTX Topco Ltd bought a new position in Verastem during the first quarter valued at $37,000. Mirabella Financial Services LLP bought a new position in Verastem during the first quarter valued at $36,000. Finally, Eaton Vance Management bought a new position in Verastem during the first quarter valued at $28,000. 58.55% of the stock is owned by institutional investors.

Verastem Trading Up 1.4 %

NASDAQ:VSTM opened at $0.41 on Monday. The company has a market cap of $85.70 million, a P/E ratio of -1.05 and a beta of 0.62. The stock’s fifty day moving average price is $0.61 and its two-hundred day moving average price is $0.99. Verastem, Inc. has a 1 year low of $0.29 and a 1 year high of $3.02. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.97 and a quick ratio of 4.97.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on VSTM. Alliance Global Partners reissued a “buy” rating and set a $6.00 price objective on shares of Verastem in a report on Wednesday, September 7th. BTIG Research reduced their price objective on Verastem from $8.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, October 5th. StockNews.com assumed coverage on Verastem in a research report on Monday. They set a “hold” rating on the stock. Finally, HC Wainwright dropped their target price on Verastem from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, November 7th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.00.

Verastem Profile

(Get Rating)

Verastem, Inc, a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK.

Read More

Want to see what other hedge funds are holding VSTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verastem, Inc. (NASDAQ:VSTMGet Rating).

Institutional Ownership by Quarter for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.